Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases

References

• Koike T. Antiphospholipid syndrome: 30 years and our contribution. Int J Rheum Dis. 2015;18(2):233–241.
   PubMed Web of Science ®Google Scholar
• Pinching AJ, Travers RL, Hughes GRV, et al. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet. 1978;1(8070):898–900.
   PubMed Web of Science ®Google Scholar
• Khamashta MA. Hughes syndrome: history. In: Khamashta MA, editor. Hughes syndrome. Antiphospholipid syndrome. London: Springer; 2000. p. 3–7.
   Google Scholar
• Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–1311.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J/Gynaecol Obstet. 2002;77(1):67–75.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
   PubMed Web of Science ®Google Scholar
• Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203(9):2165–2175.
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Nebuloni M, Cetin I, et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun. 2007;28(2–3):160–164.
   PubMed Web of Science ®Google Scholar
• Weiler JM, Edens RE, Linhardt R, et al. Heparin and modified heparin inhibit complement activation in vivo. J Immunol. 1992;148(10):3210–3215.
   PubMed Web of Science ®Google Scholar
• Linhardt RJ, Rice KG, Kim YS, et al. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro. J Biol Chem. 1988;263(26):13090–13096.
   PubMed Web of Science ®Google Scholar
• Mulla MJ, Myrtolli K, Brosens JJ, et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol. 2010;63(5):339–348.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Tonello M, Favaro M, et al. The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients: a systematic literature review analyzing 313 pregnancies. Semin Arthritis Rheum. 2021;51(1):28–35.
   PubMed Web of Science ®Google Scholar
• Alijotas-Reig J, Esteve-Valverde E, Llurba E, et al. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. Semin Arthritis Rheum. 2019;49(2):314–318.
   PubMed Web of Science ®Google Scholar
• Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost. 2017;43(6):562–571.
   PubMed Web of Science ®Google Scholar
• Belizna C, Pregnolato F, Abad S, et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev. 2018;17(12):1153–1168.
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Tosto V, Giardina I. The biological basis and prevention of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:13–22.
   PubMed Web of Science ®Google Scholar
• Tong M, Viall CA, Chamley LW. Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update. 2015;21(1):97–118.
   PubMed Web of Science ®Google Scholar
• Bulla R, de Guarrini F, Pausa M, et al. Inhibition of trophoblast adhesion to endothelial cells by the sera of women with recurrent spontaneous abortions. Am J Reprod Immunol. 1999;42(2):116–123.
   PubMed Web of Science ®Google Scholar
• Marchetti T, Ruffatti A, Wuillemin C, et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost. 2014;12(6):910–920.
   PubMed Web of Science ®Google Scholar
• Albert CR, Schlesinger WJ, Viall CA, et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol. 2014;71(2):154–164.
   PubMed Web of Science ®Google Scholar
• Torigoe M, Sakata K, Ishii A, et al. Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol. 2018;195:1–7.
   PubMed Web of Science ®Google Scholar
• De Carolis S, Rizzo F, Tabacco S. Hydroxychloroquine as additional treatment in pregnant patients with refractory APS. Am J Obstet Gynecol. 2017;217(6):711–712.
   PubMed Web of Science ®Google Scholar
• De Carolis S, Botta A, Salvi S, et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? Autoimmun Rev. 2015;14(9):760–762.
   PubMed Web of Science ®Google Scholar
• Urban ML, Bettiol A, Serena C, et al. Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: a case series and systematic review of literature. Autoimmun Rev. 2020;19(9):102620.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 2000;39(4):421–426.
   PubMed Web of Science ®Google Scholar
• Urban ML, Bettiol A, Mattioli I, et al. Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. Intern Emerg Med. 2021:11. DOI:10.1007/s11739-020-02609-4
   PubMed Web of Science ®Google Scholar
• Schreiber K, Hunt BJ. Managing antiphospholipid syndrome in pregnancy. Thromb Res. 2019;181(Suppl 1):S41–S46.
   PubMedGoogle Scholar
• Gerosa M, Meroni PL, Erkan D. Recognition and management of antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28(1):51–59.
   PubMed Web of Science ®Google Scholar
• Erkan D, Pierangeli SS. Could statins be a new therapeutic option for antiphospholipid syndrome patients? Expert Rev Hematol. 2013;6(2):115–117.
   PubMed Web of Science ®Google Scholar
• Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007;46(1):1–9.
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95(15):8880–8885.
   PubMed Web of Science ®Google Scholar
• Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci. 2014;21(1):138–145.
   PubMed Web of Science ®Google Scholar
• Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933–2940.
   PubMed Web of Science ®Google Scholar
• Tincani A, Nalli C, Khizroeva J, et al. Autoimmune diseases and pregnancy. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101322.
   PubMed Web of Science ®Google Scholar